New cocktail of drugs aims to fight tough esophageal cancer
NCT ID NCT07481058
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new oral drug called KC1036 combined with standard immunotherapy (toripalimab) and chemotherapy (paclitaxel and cisplatin) as a first treatment for advanced esophageal cancer that has spread or come back. The trial will enroll 60 adults aged 18-75 who have not had prior treatment for their advanced disease. The main goal is to see how many patients' tumors shrink or disappear, while also monitoring safety and how long the benefits last.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- KC1036 (oral drug) combined with toripalimab (immunotherapy), paclitaxel, and cisplatin (chemotherapy)
- What this could lead to
- If successful, this combination could offer a new first-line treatment option for advanced esophageal cancer, potentially shrinking tumors and delaying disease progression.
- What could go wrong
- This is an early Phase 2 trial with only 60 participants, so results may not apply to everyone. The combination of drugs may cause significant side effects, and there is no guarantee it will work better than existing treatments.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL SQUAMOUS CELL CARCINOMA (ESCC) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
RECRUITINGBeijing, 100021, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can an AI eye guide surgeons to safer, faster cancer removal?
- Can a triple punch of immunotherapy and chemoradiation wipe out esophageal tumors before surgery?
- Can early tumor response guide smarter cancer treatment?
- Could a smart combo of drugs and radiation help some esophageal cancer patients skip surgery?
- Could more surgery and radiation after immunotherapy keep esophageal cancer at bay?
- Blood and tissue markers could forecast esophageal cancer return